Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ZymoGenetics Files Recombinant Human Thrombin BLA

This article was originally published in The Pink Sheet Daily

Executive Summary

Seattle-based biotech’s rhThrombin would compete with King’s bovine-derived product.

You may also be interested in...



Johnson & Johnson/Omrix File Evicel sBLA For General Hemostasis In Surgery

Anti-bleeding product’s human serum-derived Thrombin component has a September stand-alone user fee date, Omrix tells “The Pink Sheet” DAILY.

Johnson & Johnson/Omrix File Evicel sBLA For General Hemostasis In Surgery

Anti-bleeding product’s human serum-derived Thrombin component has a September stand-alone user fee date, Omrix tells “The Pink Sheet” DAILY.

ZymoGenetics Sees Faster Approval Of Second rhThrombin Configuration

FDA’s decision to not require Phase III study for spray version could shave 18 months off of development.

Topics

UsernamePublicRestriction

Register

PS063565

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel